Methylation-associated inactivation of RASSF1A has frequently been observed in several human malignancies including sporadic colorectal and gastric cancer. However, nothing is known about the RASSF1A methylation status in the setting of MMR-deficient gastrointestinal tumours. In this study, we analysed systematically alterations in KRAS, BRAF and RASSF1A, in order to define the frequency and the pattern of these genetic/epigenetic alterations in three distinct subsets of MSI gastrointestinal tumours. Further, an association study was performed between RASSF1A methylation and the clinicopathological parameters in order to determine the profile of tumours harbouring this epigenetic event. A total of 56 MSI sporadic gastrointestinal tumours (31 colorectal and 25 gastric) and 20 MSI HNPCC analysed for KRAS/BRAF were analysed for RASSF1A promoter hypermethylation by MSP and DNA sequencing. No significant differences were found between the frequency of RASSF1A methylation in sporadic MSI colorectal and gastric carcinomas and HNPCC carcinomas (P ¼ 0.31). Methylation of RASSF1A was present in 16 of 31 (52%) sporadic MSI colorectal and 11 of 25 (44%) MSI gastric carcinomas, and in six of 20 (30%) HNPCC carcinomas. Nearly 36% of MSI sporadic colorectal carcinomas (CRCs) had RASSF1A methylation and activating mutations at KRAS and/or BRAF. In contrast, only 10 and 8% of HNPCC and sporadic gastric carcinomas, respectively, had concomitant KRAS mutations and RASSF1A methylation. The MSI sporadic gastric and CRCs with RASSF1A methylation were preferentially poorly differentiated (P ¼ 0.03, 0.05, respectively). We show that the profile of alterations RASSF1A, KRAS/BRAF is different among the three groups of MSI gastrointestinal tumours. Further, we demonstrate that MSI sporadic CRCs accumulated significantly more epigenetic/genetic alterations in RASSF1A, KRAS/BRAF than MSI sporadic gastric or HNPCC carcinomas (P ¼ 0.016). These results are likely to have therapeutic implications in the near future, due to the possibilities of using specific kinase inhibitors alone or in association with demethylating agents in MSI tumour types harbouring KRAS or BRAF mutations and RASSF1A methylation. The methylation-associated inactivation of RASSF1A gene, a novel Ras-binding protein identified at 3p21.3, has been observed in several human cancer types and strongly supports its role as a tumour suppressor gene .
Methylation-associated inactivation of RASSF1A has frequently been observed in several human malignancies including sporadic colorectal and gastric cancer. However, nothing is known about the RASSF1A methylation status in the setting of MMR-deficient gastrointestinal tumours. In this study, we analysed systematically alterations in KRAS, BRAF and RASSF1A, in order to define the frequency and the pattern of these genetic/epigenetic alterations in three distinct subsets of MSI gastrointestinal tumours. Further, an association study was performed between RASSF1A methylation and the clinicopathological parameters in order to determine the profile of tumours harbouring this epigenetic event. A total of 56 MSI sporadic gastrointestinal tumours (31 colorectal and 25 gastric) and 20 MSI HNPCC analysed for KRAS/BRAF were analysed for RASSF1A promoter hypermethylation by MSP and DNA sequencing. No significant differences were found between the frequency of RASSF1A methylation in sporadic MSI colorectal and gastric carcinomas and HNPCC carcinomas (P ¼ 0.31). Methylation of RASSF1A was present in 16 of 31 (52%) sporadic MSI colorectal and 11 of 25 (44%) MSI gastric carcinomas, and in six of 20 (30%) HNPCC carcinomas. Nearly 36% of MSI sporadic colorectal carcinomas (CRCs) had RASSF1A methylation and activating mutations at KRAS and/or BRAF. In contrast, only 10 and 8% of HNPCC and sporadic gastric carcinomas, respectively, had concomitant KRAS mutations and RASSF1A methylation. The MSI sporadic gastric and CRCs with RASSF1A methylation were preferentially poorly differentiated (P ¼ 0.03, 0.05, respectively). We show that the profile of alterations RASSF1A, KRAS/BRAF is different among the three groups of MSI gastrointestinal tumours. Further, we demonstrate that MSI sporadic CRCs accumulated significantly more epigenetic/genetic alterations in RASSF1A, KRAS/BRAF than MSI sporadic gastric or HNPCC carcinomas (P ¼ 0.016). These results are likely to have therapeutic implications in the near future, due to the possibilities of using specific kinase inhibitors alone or in association with demethylating agents in MSI tumour types harbouring KRAS or BRAF mutations and RASSF1A methylation. The methylation-associated inactivation of RASSF1A gene, a novel Ras-binding protein identified at 3p21.3, has been observed in several human cancer types and strongly supports its role as a tumour suppressor gene .
RASSF1 gene generates several isoforms due to alternative splicing and differential promoter usage. RASSF1A, the longest isoform of RASSF1, apart from reducing tumorigenesis in vivo and in vitro (Dammann et al., 2000; Lerman and Minna, 2000) is able to inhibit cell cycle progression by inhibiting cyclin D1 accumulation (Shivakumar et al., 2002) . Moreover, RASSF1A one of the two major isoforms of RASSF1 contain a Ras-binding domain that can associate to active Ras in vitro (Vos et al., 2000) , similar to the domain found within Raf-1 allowing the activation of Raf-1 by Ras (Williams et al., 2000) .
RASSF1A inactivation, through promoter hypermethylation, is a frequent alteration observed in sporadic colorectal (SCRC) and gastric cancers (SGC) (Byun et al., 2002; Van Engeland et al., 2002) .
KRAS and BRAF mutations, activating the RAS/ RAF/MAPK pathway, are the most frequent oncogenic events in SCRC (Rajagopalan et al., 2002; Yuen et al., 2002; Oliveira et al., 2003) . MSI SCRCs show in 40% of the cases BRAF activating mutations that are alternative to KRAS mutations (Deng et al., 2004; Domingo et al., 2004a, b; Koinuma et al., 2004) . On the other hand, HNPCC and MSI SGC show exclusively KRAS activating mutations in 30-40% of the cases, respectively Domingo et al., 2004b; Oliveira et al., 2004) .
The relationship between RASSF1A promoter methylation and KRAS/BRAF mutations has been addressed in some tumour models. In SCRC and pancreatic carcinomas, it was shown that RASSF1A promoter hypermethylation occurs predominantly in tumours with KRAS wild type (Van Engeland et al., 2002; Dammann et al., 2003) , while in melanoma, most tumours harbour concomitant BRAF or NRAS mutations and RASSF1A methylation, suggesting a possible synergistic effect (Reifenberger et al., 2004) . In thyroid cancer, a mutual exclusion of BRAF mutations and RASSF1A methylation has been reported (Xing et al., 2004) .
The frequency of RASSF1A promoter methylation is not known in MSI gastrointestinal tumours nor its association with KRAS and BRAF oncogenic mutations. In this study, we analysed systematically alterations in KRAS, BRAF and RASSF1A, in order to define the frequency and the pattern of genetic/epigenetic alterations in three distinct subsets of MSI gastrointestinal tumours.
To address the frequency of RASSF1A promoter methylation, we analysed 76 gastrointestinal primary tumours with microsatellite instability: 31 MSI SCRC, 20 MSI CRCs from HNPCC patients with germline mutations in hMLH1 (n ¼ 9) and hMSH2 (n ¼ 11), and 25 MSI SGC. Figure 1 shows examples of cases with RASSF1A methylation.
MSI CRCs in general (sporadic and hereditary) showed RASSF1A promoter methylation in 43.1% of the cases (22/51). The frequency of RASSF1A methylation in MSI colorectal cancers, herein described, is higher in comparison to the frequencies previously reported in a series of colorectal tumours (20.3%) without characterization of MSI phenotype (Van Engeland et al., 2002) , suggesting that methylation affecting RASSF1A promoter may preferentially occur within the context of MSI colorectal tumorigenesis. MSI SCRC showed RASSF1A promoter methylation in 51.6% (16/ 31) of the cases, while HNPCC CRC showed methylation in 30.0% (6/20) ( Table 1 ). The lower frequency of methylation in the promoter region of RASSF1A found in HNPCC is in accordance with the results described by McGivern et al. (2004) showing that widespread methylation of other promoter regions occurred less frequently within HNPCC tumours compared with sporadic MSI tumours. Furthermore, mutation carriers of hMLH1 and hMSH2 showed similar frequency of RASSF1A promoter methylation, 33.3 and 27.3%, respectively.
Of 25 MSI SGC, 11 (44.0%) showed RASSF1A methylated sequences. This frequency is similar to the frequency previously reported in a series of 90 gastric tumours (Byun et al., 2002) , without characterization of MSI phenotype. Knowing that only 15-20% of all gastric carcinomas show the MSI phenotype, the finding of a similar frequency of RASSF1A promoter methylation in both series demonstrates that this epigenetic alteration is a frequent event in gastric tumorigenesis, and that it is independent of MMR deficiency.
The knowledge that RASSF1 can either associate with oncogenic/mutant KRAS or with KRAS-GTP bound through heterodimerization with Nore, a RASS-F1A and Ras-GTP-binding protein (Ortiz-Vega et al., 2002) , places RASSF1A in the MAPK pathway through RAS. This assumption raises the hypothesis of analysing alterations at KRAS-BRAF-RASSF1A genes as partners in the same pathway.
The frequency of cases accumulating genetic/epigenetic alterations in KRAS-BRAF-RASSF1A in the three subsets of MSI tumours was significantly different (P ¼ 0.016). In MSI SCRC, 11 of the 31 (35.5%) cases analysed had RASSF1A methylation in accumulation with mutations in either KRAS (n ¼ 1), or BRAF (n ¼ 8) or both KRAS and BRAF (n ¼ 2). In HNPCC and MSI SGC, accumulation of RASSF1A methylation and Figure 1 RASSF1A promoter methylation analysis in gastrointestinal tumours by MSP and sequencing. Promoter methylation of the RASSF1A gene was performed using bis-sulfite-modified genomic DNA as template and subsequent methylation specific PCR and DNA sequencing as described (De Caceres et al., 2004) . The primers used were 5 0 -GTT TAG TTT GGA TTT TGG GGG AG-3 0 (sense primer) and 5 0 -CCC TCA ACT CAA TAA ACT CAA ACT C-3 0 (antisense primer). The annealing temperature was 561C and the resulting fragment was used as a template for the MSP reaction. Primer sequences for the unmethylated reaction were 5 0 -GGG GTT TGT TTT GTG GTT TTG TTT-3 0 (sense primer) and 5 0 -AAC ATA ACC CAA TTA AAC CCA TAC TTC A-3 0 (antisense primer). Primer sequences for the methylated reaction were 5 0 -GGG TTC GTT TTG TGG TTT CGT TC-3 0 (sense primer) and 5 0 -TAA CCC GAT TAA ACC CGT ACT TCG-3 0 (antisense primer). All PCR reactions were performed with controls for unmethylated RASSF1A alleles (DNA from normal lymphocytes) and methylated RASSF1A alleles (DNA from normal lymphocytes treated with Sss1 methyltransferase (New England Biolabs)). PCR products were analysed in 2% agarose gels. Samples with methylated and unmethylated alleles were resubmitted to PCR and products were purified and sequenced on an ABI Prism 377 automated sequencer (Perkin-Elmer, Foster City, CA, USA) using the ABI prism dye terminator cycle sequencing kit (Perkin-Elmer) using the original primers. Figure 2) . Similarly to what was described in the melanoma cell model, our study shows for the first time, for the best of our knowledge, that a considerable fraction of MSI SCRC cases harbours concomitant RASSF1A methylation and BRAF and/or KRAS mutations. These data suggest a synergistic effect between the silencing of the tumour suppressor gene RASSF1A and activation of an oncogene KRAS or BRAF, in the setting of SCRC with MMR deficiency. The majority of HNPCC and MSI SGC carcinomas showed single genetic or epigenetic alterations at KRAS-BRAF-RASSF1A genes (Table 1, Figure 2 ), which may, in part, be explained by the lack of BRAF mutations in these two tumour models Deng et al., 2004; Domingo et al., 2004a, b) . Among HNPCCs, while accumulation of RASSF1A methylation and KRAS mutations occurs in 18% (2/11) of HNPCC tumours carrying germline hMSH2 mutations, this accumulation was never (0/9) observed in tumours from patients with hMLH1 germline mutations (Table 1, Figure 2 ). This result may reflect previous observations showing that tumours from hMLH1 mutation carriers have lower frequency of KRAS mutations in comparison with tumours from hMSH2 mutation carriers (Oliveira et al., 2004) . Further, the profile of alterations in the KRAS-BRAF-RASSF1A pathway was distinct in HNPCC carcinomas and MSI SGC (Table 1, Figure 2 ). Whereas 50% of HNPCC show preferential single mutations in KRAS, 60% of MSI SGC show preferentially RASSF1A methylation (Table 1, Figure 2) .
The role of RASSF1A as a tumour suppressor gene frequently inactivated in MSI sporadic gastrointestinal tumours questions whether RASSF1A inactivation (methylation) is associated with a particular tumour phenotype or with specific clinicopathological features (Tables 2 and 3) . No significant associations were found between RASSF1A methylation with the following clinicopathologic characteristics of the patients and tumours: age and gender of the patients, tumour location, wall invasion, presence of lymph node metastases and staging of the tumours (Tables 2 and 3) .
We found a significant association between the presence of RASSF1A methylation and a poor degree of differentiation of the gastric and colon tumours (P ¼ 0.03 and 0.05, respectively) (Tables 2 and 3) , as previously shown either in colorectal and gastric carcinomas (Byun et al., 2002; Dammann et al., 2003) . In gastric carcinoma, this significant difference can be due, in part, to a higher frequency of cases with RASSF1A methylation in more advance carcinomas (Table 2) . However, in colorectal tumours, this observa- Figure 2 Frequency and profile of genetic/epigenetic alterations in MSI gastrointestinal tumours. In all, 31 MSIsporadic CRCs, 25 MSI gastric carcinomas and 20 HNPCC CRCs with germline mutations in hMLH1 (n ¼ 9) and hMSH2 (n ¼ 11) were analysed for RASSF1A promoter methylation. The study protocol was reviewed and approved by the appropriate Ethics Committees. A family history was obtained for every patient with SCRC and SGC, and none of them had a family history suggestive of hereditary nonpolyposis colorectal cancer or familial gastric cancer. Haematoxylin-and eosin-stained sections were used to classify the tumours and allowed their macrodissection. High molecular weight DNA was isolated using standard methods from total sections of the tumours whenever tumour cells occupied more than 50% of tumour tissue or from macrodissected areas with at least 50% of tumour cells. All tumours were analysed for microsatellite instability according to the international criteria for the determination of microsatellite instability, using various panels of dinucleotide and mononucleotide repeat sequences (Umar et al., 2004) . Mutational analysis of BRAF exon 15 and KRAS codons 12 and 13 was performed by PCR/SSCP/Sequencing as described previously (Oliveira et al., , 2004 . Associations between the RASSF1A promoter methylation and mutations in KRAS and/or BRAF in the three subsets of MSI carcinomas were assessed by the w 2 test. A Pvalue p0.05 was considered statistically significant KRAS-BRAF-RASSF1A in MSI gastrointestinal cancers C Oliveira et al tion does not imply that inactivation of RASSF1A occurs in late stages of CRC progression, because 62.5% of CRC showing RASSF1A methylation are stage I tumours (Table 3) . Since no expression studies were performed in order to characterize RASSF1A expression levels, any conclusion based on the correlation of complete RASSF1A inactivation and poor differentiation of the tumours has to be cautious. In summary, this is the first study addressing RASSF1A methylation in a series of MMR-deficient gastrointestinal tumours, both sporadic and hereditary. We show that methylation of RASSF1A promoter occurs within all types of MSI carcinomas: SCRC, HNPCC and SGC. We demonstrate that MSI SCRC cases accumulate significantly more epigenetic/genetic alterations in RASSF1A and KRAS and/or BRAF than MSI SGC or HNPCC carcinomas. Further, we show that more than 50% of MSI SGC harbour methylation in RASSF1A and HNPCC carcinomas harbour preferentially KRAS mutations. We additionally confirm the association of RASSF1A methylation and poor differentiation of SCRC and SGC. Our results are likely to have therapeutic implications in the near future, since they show that the profile of alterations of RASSF1A-KRAS-BRAF alterations is distinct within the three groups of MSI gastrointestinal tumours. Associations between the RASSF1A promoter methylation and the clinicopathological features of the SCRC were assessed by the w 2 test. A P-value p0.05 was considered statistically significant. a Associations between the RASSF1A promoter methylation and the clinicopathological features of the SCRC were assessed by the w 2 test. A P-value p0.05 was considered statistically significant.
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